首页> 外文期刊>General Pharmacology >Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission.
【24h】

Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission.

机译:pukateine的多巴胺能药理学和抗氧化特性,一种用于增加多巴胺神经传递的药物设计的天然产物。

获取原文
获取原文并翻译 | 示例
       

摘要

The dopaminergic and antioxidant properties of pukateine [(R)-11-hydroxy-1,2-methylenedioxyaporphine, PUK], a natural aporphine derivative, were analyzed in the rat central nervous system. At dopamine (DA) D1 ([3H]-SCH 23390) and D2 ([3H]-raclopride) binding sites, PUK showed IC50 values in the submicromolar range (0.4 and 0.6 microM, respectively). When the uptake of tritiated dopamine was assayed by using a synaptosomal preparation, PUK showed an IC50 = 46 microM. In 6-hydroxydopamine unilaterally denervated rats, PUK (8 mg/kg but not 4 mg/kg) elicited a significant contralateral circling, a behavior classically associated with a dopaminergic agonist action. When perfused through a microdialysis probe inserted into the striatum, PUK (340 microM) induced a significant increase in dopamine levels. In vitro experiments with a crude rat brain mitochondrial suspension showed that PUK did not affect monoamine oxidase activities, at concentrations as high as 100 microM. PUK potently (IC50 = 15 microM) and dose-dependently inhibited the basal lipid peroxidation of a rat brain membrane preparation. As a whole, PUK showed a unique profile of action, comprising an increase in extracellular DA, an agonist-like interaction with DA receptors, and antioxidant activity. Thus, PUK may be taken as a lead compound for the development of novel therapeutic strategies for Parkinson disease.
机译:在大鼠中枢神经系统中分析了天然的阿芬啡衍生物-普卡汀[[R-11--11--羟基-1,2-亚甲基二氧基aporphine,PUK]]的多巴胺能和抗氧化特性。在多巴胺(DA)D1([3H] -SCH 23390)和D2([3H]-雷氯必利)结合位点,PUK的IC50值在亚微摩尔范围内(分别为0.4和0.6 microM)。使用突触体制剂测定assay化多巴胺的摄取时,PUK的IC50 = 46 microM。在6-羟基多巴胺单侧神经支配的大鼠中,PUK(8 mg / kg而非4 mg / kg)引起明显的对侧盘旋,这种行为通常与多巴胺能激动剂作用有关。当通过插入纹状体的微透析探针进行灌注时,PUK(340 microM)导致多巴胺水平显着增加。在大鼠脑线粒体悬浮液中进行的体外实验表明,PUK在浓度高达100 microM时不会影响单胺氧化酶的活性。 PUK有效(IC50 = 15 microM)并剂量依赖性地抑制大鼠脑膜制剂的基础脂质过氧化。总体而言,PUK表现出独特的作用特征,包括细胞外DA的增加,与DA受体的激动剂样相互作用以及抗氧化活性。因此,PUK可以作为开发帕金森病新治疗策略的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号